CA2554718A1 - Nouvelles sequences de nucleotides et d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic - Google Patents
Nouvelles sequences de nucleotides et d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic Download PDFInfo
- Publication number
- CA2554718A1 CA2554718A1 CA002554718A CA2554718A CA2554718A1 CA 2554718 A1 CA2554718 A1 CA 2554718A1 CA 002554718 A CA002554718 A CA 002554718A CA 2554718 A CA2554718 A CA 2554718A CA 2554718 A1 CA2554718 A1 CA 2554718A1
- Authority
- CA
- Canada
- Prior art keywords
- segment
- found
- transcript
- libraries
- node
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 121
- 238000003745 diagnosis Methods 0.000 title abstract description 15
- 239000002773 nucleotide Substances 0.000 title description 43
- 125000003729 nucleotide group Chemical group 0.000 title description 40
- 238000003556 assay Methods 0.000 title description 38
- 125000003275 alpha amino acid group Chemical group 0.000 title description 8
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 118
- 108091034117 Oligonucleotide Proteins 0.000 claims description 125
- 230000014509 gene expression Effects 0.000 claims description 103
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 82
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 102000040430 polynucleotide Human genes 0.000 claims description 21
- 108091033319 polynucleotide Proteins 0.000 claims description 21
- 239000002157 polynucleotide Substances 0.000 claims description 21
- 238000005516 engineering process Methods 0.000 claims description 17
- 108091093088 Amplicon Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 43
- 108090000623 proteins and genes Proteins 0.000 description 606
- 102000004169 proteins and genes Human genes 0.000 description 580
- 108091026890 Coding region Proteins 0.000 description 189
- 108091092724 Noncoding DNA Proteins 0.000 description 133
- 230000000875 corresponding effect Effects 0.000 description 119
- 239000000523 sample Substances 0.000 description 82
- 102000039446 nucleic acids Human genes 0.000 description 75
- 108020004707 nucleic acids Proteins 0.000 description 75
- 206010028980 Neoplasm Diseases 0.000 description 73
- 201000011510 cancer Diseases 0.000 description 71
- 108091060211 Expressed sequence tag Proteins 0.000 description 70
- 210000001519 tissue Anatomy 0.000 description 67
- 102000053602 DNA Human genes 0.000 description 59
- 108020004414 DNA Proteins 0.000 description 59
- 238000003752 polymerase chain reaction Methods 0.000 description 58
- 238000009396 hybridization Methods 0.000 description 57
- 239000003550 marker Substances 0.000 description 52
- 230000003321 amplification Effects 0.000 description 51
- 238000003199 nucleic acid amplification method Methods 0.000 description 51
- 238000001514 detection method Methods 0.000 description 47
- 239000013615 primer Substances 0.000 description 34
- 229920002477 rna polymer Polymers 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 29
- 230000035772 mutation Effects 0.000 description 29
- 238000007834 ligase chain reaction Methods 0.000 description 28
- 210000003205 muscle Anatomy 0.000 description 28
- 239000012634 fragment Substances 0.000 description 24
- 102100026126 Proline-tRNA ligase Human genes 0.000 description 21
- 210000004072 lung Anatomy 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 239000002253 acid Substances 0.000 description 19
- -1 cells Substances 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 18
- 210000001072 colon Anatomy 0.000 description 18
- 238000002493 microarray Methods 0.000 description 18
- 239000012472 biological sample Substances 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 17
- 230000000295 complement effect Effects 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 16
- 210000004291 uterus Anatomy 0.000 description 16
- 210000000481 breast Anatomy 0.000 description 15
- 230000002018 overexpression Effects 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000001919 adrenal effect Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 13
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 210000000496 pancreas Anatomy 0.000 description 13
- 210000002307 prostate Anatomy 0.000 description 13
- 239000003463 adsorbent Substances 0.000 description 12
- 210000005003 heart tissue Anatomy 0.000 description 12
- 210000001672 ovary Anatomy 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 230000002285 radioactive effect Effects 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 238000013515 script Methods 0.000 description 11
- 239000003155 DNA primer Substances 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002751 oligonucleotide probe Substances 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 239000001488 sodium phosphate Substances 0.000 description 10
- 229910000162 sodium phosphate Inorganic materials 0.000 description 10
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 9
- 108010015514 Glutamate-tRNA ligase Proteins 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000000729 Fisher's exact test Methods 0.000 description 8
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 description 8
- 108091006296 SLC2A1 Proteins 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 229940104302 cytosine Drugs 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
- 210000001685 thyroid gland Anatomy 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000000123 temperature gradient gel electrophoresis Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 6
- 241000972773 Aulopiformes Species 0.000 description 6
- 102100029331 Plakophilin-1 Human genes 0.000 description 6
- 108030004374 Proline-tRNA ligases Proteins 0.000 description 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 229960000643 adenine Drugs 0.000 description 6
- 150000001408 amides Chemical group 0.000 description 6
- 230000031018 biological processes and functions Effects 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 101150027734 cript gene Proteins 0.000 description 6
- 230000001351 cycling effect Effects 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000013861 fat-free Nutrition 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 235000019515 salmon Nutrition 0.000 description 6
- 229940035893 uracil Drugs 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 102100036912 Desmin Human genes 0.000 description 5
- 108010044052 Desmin Proteins 0.000 description 5
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 5
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 5
- 108010004729 Phycoerythrin Proteins 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 5
- 230000037230 mobility Effects 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 235000008476 powdered milk Nutrition 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 4
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 4
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 101710144641 Late transcription elongation factor G2 Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 108010057275 Plakophilins Proteins 0.000 description 4
- 102100033954 Protein PRRC2A Human genes 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 4
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000002820 assay format Methods 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000003398 denaturant Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 125000001475 halogen functional group Chemical group 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 230000004879 molecular function Effects 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 125000004437 phosphorous atom Chemical group 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 229940113082 thymine Drugs 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 3
- 108091052347 Glucose transporter family Proteins 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 101710095135 NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 3
- 208000031662 Noncommunicable disease Diseases 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- 101710115782 Proline-tRNA ligase Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000037429 base substitution Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000003963 intermediate filament Anatomy 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 238000013188 needle biopsy Methods 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 238000002515 oligonucleotide synthesis Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108010042589 prolyl T RNA synthetase Proteins 0.000 description 3
- 150000003212 purines Chemical class 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 125000006853 reporter group Chemical group 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000029305 taxis Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 2
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 2
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 2
- DWAOUXYZOSPAOH-UHFFFAOYSA-N 4-[2-(diethylamino)ethoxy]furo[3,2-g]chromen-7-one;hydrochloride Chemical compound [Cl-].O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC[NH+](CC)CC DWAOUXYZOSPAOH-UHFFFAOYSA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 2
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 2
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 2
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 2
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 2
- 229960005508 8-azaguanine Drugs 0.000 description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 230000004668 G2/M phase Effects 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 101150098207 NAAA gene Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 108091028733 RNTP Proteins 0.000 description 2
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 241000287181 Sturnus vulgaris Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 241000689006 Syntrophorhabdaceae Species 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000009693 chronic damage Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000002726 cyst fluid Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 210000001047 desmosome Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004880 lymph fluid Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 150000008298 phosphoramidates Chemical class 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 2
- 150000003456 sulfonamides Chemical group 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 150000003457 sulfones Chemical group 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 235000012976 tarts Nutrition 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- QSHACTSJHMKXTE-UHFFFAOYSA-N 2-(2-aminopropyl)-7h-purin-6-amine Chemical compound CC(N)CC1=NC(N)=C2NC=NC2=N1 QSHACTSJHMKXTE-UHFFFAOYSA-N 0.000 description 1
- FDZGOVDEFRJXFT-UHFFFAOYSA-N 2-(3-aminopropyl)-7h-purin-6-amine Chemical compound NCCCC1=NC(N)=C2NC=NC2=N1 FDZGOVDEFRJXFT-UHFFFAOYSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- RPDFNWYMPMQRQO-UHFFFAOYSA-N 2-n,2-n,2-n',2-n'-tetrafluoro-1,3-bis(2-fluoro-2,2-dinitroethoxy)propane-2,2-diamine Chemical compound [O-][N+](=O)C(F)([N+]([O-])=O)COCC(N(F)F)(N(F)F)COCC(F)([N+]([O-])=O)[N+]([O-])=O RPDFNWYMPMQRQO-UHFFFAOYSA-N 0.000 description 1
- MJEQLGCFPLHMNV-UHFFFAOYSA-N 4-amino-1-(hydroxymethyl)pyrimidin-2-one Chemical compound NC=1C=CN(CO)C(=O)N=1 MJEQLGCFPLHMNV-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 101001125937 Bos taurus Plakophilin-1 Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- UDHXJZHVNHGCEC-UHFFFAOYSA-N Chlorophacinone Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)C(=O)C1C(=O)C2=CC=CC=C2C1=O UDHXJZHVNHGCEC-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000543381 Cliftonia monophylla Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 102100033149 Cytochrome b5 reductase 4 Human genes 0.000 description 1
- 108030005700 Cytochrome-b5 reductases Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 241001633942 Dais Species 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100173450 Drosophila melanogaster Gmer gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000001411 G2 and S phase-expressed protein 1 Human genes 0.000 description 1
- 102100037488 G2 and S phase-expressed protein 1 Human genes 0.000 description 1
- 108050009617 G2 and S phase-expressed protein 1 Proteins 0.000 description 1
- 230000012118 G2 phase of mitotic cell cycle Effects 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001125939 Homo sapiens Plakophilin-1 Proteins 0.000 description 1
- 101000906283 Homo sapiens Solute carrier family 2, facilitated glucose transporter member 1 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000582786 Monoplex Species 0.000 description 1
- 101100029838 Mus musculus Pinx1 gene Proteins 0.000 description 1
- 241001325209 Nama Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241001069925 Orestes Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
- 241001674788 Pasites Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108050004756 Plakophilin-1 Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102000015097 RNA Splicing Factors Human genes 0.000 description 1
- 108010039259 RNA Splicing Factors Proteins 0.000 description 1
- 241000662740 Sabatia campestris Species 0.000 description 1
- 101710104314 Solute carrier family 2, facilitated glucose transporter member 1 Proteins 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical group O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- RLXCFCYWFYXTON-JTTSDREOSA-N [(3S,8S,9S,10R,13S,14S,17R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-16-yl] N-hexylcarbamate Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC(=O)NCCCCCC)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 RLXCFCYWFYXTON-JTTSDREOSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 108010066657 azoreductase Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004274 microtubule-based process Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- DVGMLNVTRLVBSG-UHFFFAOYSA-N prop-2-enylideneiron Chemical compound C(=C)C=[Fe] DVGMLNVTRLVBSG-UHFFFAOYSA-N 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000022814 xenobiotic metabolic process Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53912904P | 2004-01-27 | 2004-01-27 | |
US60/539,129 | 2004-01-27 | ||
US62866604P | 2004-11-18 | 2004-11-18 | |
US60/628,666 | 2004-11-18 | ||
PCT/IB2005/002438 WO2006035273A2 (fr) | 2004-01-27 | 2005-01-27 | Nouvelles sequences de nucleotides et d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic |
US11/043,788 US20060014166A1 (en) | 2004-01-27 | 2005-01-27 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis |
US---- | 2020-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2554718A1 true CA2554718A1 (fr) | 2006-04-06 |
Family
ID=36119256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002554718A Abandoned CA2554718A1 (fr) | 2004-01-27 | 2005-01-27 | Nouvelles sequences de nucleotides et d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1716256A2 (fr) |
AU (1) | AU2005288710A1 (fr) |
CA (1) | CA2554718A1 (fr) |
WO (1) | WO2006035273A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
-
2005
- 2005-01-27 AU AU2005288710A patent/AU2005288710A1/en not_active Abandoned
- 2005-01-27 EP EP05805030A patent/EP1716256A2/fr not_active Withdrawn
- 2005-01-27 CA CA002554718A patent/CA2554718A1/fr not_active Abandoned
- 2005-01-27 WO PCT/IB2005/002438 patent/WO2006035273A2/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2005288710A1 (en) | 2006-04-06 |
EP1716256A2 (fr) | 2006-11-02 |
WO2006035273A3 (fr) | 2009-04-16 |
WO2006035273A2 (fr) | 2006-04-06 |
AU2005288710A2 (en) | 2006-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060046257A1 (en) | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer | |
US7842459B2 (en) | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis | |
US20060263786A1 (en) | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of colon cancer | |
US20090029371A1 (en) | Method for determining vasoreactivity | |
US6627401B2 (en) | Method for detecting a single nucleotide polymorphism in p21waf1/cip1 gene as an indicator of risk of esophageal cancer | |
US20040110227A1 (en) | Methods and systems for identifying putative fusion transcripts, polypeptides encoded therefrom and polynucleotide sequences related thereto and methods and kits utilizing same | |
WO2010061393A1 (fr) | Séquences d'acides aminés et de nucléotides de variants de he4 et leurs procédés d'utilisation | |
CA2554703A1 (fr) | Expression differentielle de marqueurs dans le cancer de l'ovaire | |
WO2006131783A2 (fr) | Nouvelles sequences d'aminoacides et de nucleotides, et dosages et methodes d'utilisation afferentes dans le diagnostic du cancer du poumon | |
US6617104B2 (en) | Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus | |
US6544742B1 (en) | Detection of genes regulated by EGF in breast cancer | |
CA2554718A1 (fr) | Nouvelles sequences de nucleotides et d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic | |
CA2554440A1 (fr) | Nouvelles sequences nucleotidiques et d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic du cancer du sein | |
WO2006043271A1 (fr) | Nouvelles sequences d'acides amines et sequences nucleotidiques et methodes d'utilisation de celles-ci pour le diagnostic | |
US20030032099A1 (en) | Methods for predicting susceptibility to obesity and obesity-associated health problems | |
US9045554B2 (en) | Ribonucleic acid binding motif protein 20 sequence variants | |
EP1749025A2 (fr) | Nouveaux nucleotides et sequences d'acides amines, et leurs dosages et procedes d'utilisation pour le diagnostic du cancer du colon | |
CN106957907B (zh) | 用于狗中的肝铜积累的遗传检测 | |
Fujihara et al. | Global analysis of single nucleotide polymorphisms in the exons of human deoxyribonuclease I‐like 1 and 2 genes | |
KR20210154527A (ko) | 스타틴 약물 부작용 예측을 위한 유전자 마커 | |
WO2010071405A1 (fr) | Marqueurs pour détecter une prédisposition au risque, une apparition et une progression d'ostéoarthrite | |
KR102409336B1 (ko) | 면역글로불린 a 신병증 및 혈관염 진단용 snp 마커 및 이를 이용한 진단 방법 | |
KR101232100B1 (ko) | 관상 심장 질환과 단백질 다형성의 연관성 | |
JP4317376B2 (ja) | 糖尿病性腎症遺伝子の検出方法 | |
KR100912470B1 (ko) | 정신분열증 진단용 snp와 그를 포함하는 마이크로어레이및 키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |